Atox Bio Ltd
Quick facts
Phase 2 pipeline
- AB103 · Oncology
AB103 is a monoclonal antibody targeting the PD-1 receptor.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Related
- Sector hub: All tracked pharma companies